Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...